Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 143

1.

Research and development productivity map: visualization of industry status.

Shimura H, Masuda S, Kimura H.

J Clin Pharm Ther. 2014 Apr;39(2):175-80. doi: 10.1111/jcpt.12126.

PMID:
24438433
2.
3.

The case for entrepreneurship in R&D in the pharmaceutical industry.

Douglas FL, Narayanan VK, Mitchell L, Litan RE.

Nat Rev Drug Discov. 2010 Sep;9(9):683-9. doi: 10.1038/nrd3230.

PMID:
20725093
4.

How to improve R&D productivity: the pharmaceutical industry's grand challenge.

Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, Schacht AL.

Nat Rev Drug Discov. 2010 Mar;9(3):203-14. doi: 10.1038/nrd3078.

PMID:
20168317
5.

Models for open innovation in the pharmaceutical industry.

Schuhmacher A, Germann PG, Trill H, Gassmann O.

Drug Discov Today. 2013 Dec;18(23-24):1133-7. doi: 10.1016/j.drudis.2013.07.013.

PMID:
23892183
6.

The impact of mergers on pharmaceutical R&D.

LaMattina JL.

Nat Rev Drug Discov. 2011 Aug 1;10(8):559-60. doi: 10.1038/nrd3514.

PMID:
21804580
7.

The productivity crisis in pharmaceutical R&D.

Pammolli F, Magazzini L, Riccaboni M.

Nat Rev Drug Discov. 2011 Jun;10(6):428-38. doi: 10.1038/nrd3405. Review.

PMID:
21629293
8.

R&D productivity rides again?

Lendrem D, Senn SJ, Lendrem BC, Isaacs JD.

Pharm Stat. 2015 Jan-Feb;14(1):1-3. doi: 10.1002/pst.1653. Review.

PMID:
25336017
9.

Accessing external innovation in drug discovery and development.

Tufféry P.

Expert Opin Drug Discov. 2015 Jun;10(6):579-89. doi: 10.1517/17460441.2015.1040759. Review.

PMID:
25910932
10.

The development speed paradox: can increasing development speed reduce R&D productivity?

Lendrem DW, Lendrem BC.

Drug Discov Today. 2014 Mar;19(3):209-14. doi: 10.1016/j.drudis.2013.09.002.

PMID:
24051396
11.

Mergers and innovation in the pharmaceutical industry.

Comanor WS, Scherer FM.

J Health Econ. 2013 Jan;32(1):106-13. doi: 10.1016/j.jhealeco.2012.09.006.

PMID:
23220457
12.

Improving R&D productivity of pharmaceutical companies through public-private partnership: experiences from the Innovative Medicines Initiative.

Laverty H, Gunn M, Goldman M.

Expert Rev Pharmacoecon Outcomes Res. 2012 Oct;12(5):545-8. doi: 10.1586/erp.12.59. No abstract available.

PMID:
23136843
13.

Rebuilding the R&D engine in big pharma.

Garnier JP.

Harv Bus Rev. 2008 May;86(5):68-70, 72-6, 128.

PMID:
18543809
14.

Drug discovery: are productivity metrics inhibiting motivation and creativity?

Ullman F, Boutellier R.

Drug Discov Today. 2008 Nov;13(21-22):997-1001. doi: 10.1016/j.drudis.2008.06.015.

PMID:
18652910
15.

Virtual pharmaceutical companies: collaborating flexibly in pharmaceutical development.

Forster SP, Stegmaier J, Spycher R, Seeger S.

Drug Discov Today. 2014 Mar;19(3):348-55. doi: 10.1016/j.drudis.2013.11.015. Review.

PMID:
24291787
16.

Does size matter in R&D productivity? If not, what does?

Ringel M, Tollman P, Hersch G, Schulze U.

Nat Rev Drug Discov. 2013 Dec;12(12):901-2. doi: 10.1038/nrd4164. No abstract available.

PMID:
24136396
17.

The changing structure of the pharmaceutical industry.

Cockburn IM.

Health Aff (Millwood). 2004 Jan-Feb;23(1):10-22.

18.

How should we support pharmaceutical innovation?

Grootendorst P.

Expert Rev Pharmacoecon Outcomes Res. 2009 Aug;9(4):313-20. doi: 10.1586/erp.09.34.

PMID:
19670991
19.

A decade of innovation in pharmaceutical R&D: the Chorus model.

Owens PK, Raddad E, Miller JW, Stille JR, Olovich KG, Smith NV, Jones RS, Scherer JC.

Nat Rev Drug Discov. 2015 Jan;14(1):17-28. doi: 10.1038/nrd4497. Review.

PMID:
25503514
20.
Items per page

Supplemental Content

Support Center